Abstracts tagged "Early Rheumatoid Arthritis and galectin"

Abstract Number: 2573 • 2016 ACR/ARHP Annual Meeting
Galectin 1 As Potential Prognostic Biomarker in Rheumatoid Arthritis
Amalia Lamana¹, Ana Triguero-Martinez², Iria V. Seoane³, Hortensia de la Fuente⁴, Carmen Martinez-Mora⁵, Ana M. Ortiz Garcia⁶, Rosario García-Vicuña⁶, Rosa P Gomariz⁷ and Isidoro Gonzalez-Alvaro⁶, ¹Rheumatology, Hospital Universitario de La Princesa. IIS Princesa, Madrid, Spain, ²Rheumatology Service, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa, Madrid, Spain, ³Department of Cell Biology, Faculty of Biology, Universidad Complutense de Madrid, Madrid, Spain, ⁴Immunology, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa, Madrid, Spain, ⁵Cellular Biology, School of Medicine. Universidad Complutense de Madrid, Madrid, Spain, ⁶Rheumatology, Rheumatology Service, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ⁷Cellular Biology, School of Biology. Universidad Complutense de Madrid, Madrid, Spain
Background/Purpose: Galectin 1 (Gal1) is a type of lectin expressed in a wide variety of tissues and organs. In the immune context, is broadly described…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].